SOUTH SAN FRANCISCO, Calif. — November 21, 2023 — Epicrispr Biotechnologies, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today announced a presentation at the upcoming CRISPR2.0 conference being held November 28-30, 2023, at the Hilton Boston Back Bay, Boston Massachusetts.
Title: GEMS: CRISPR Epigenetics Platform to Revolutionize Genetic Medicine
Track: Tech Innovation
Session: Epigenetics: Harnessing Nature’s Mechanism for Genome Regulation
Session Date: Wednesday, November 29, 2023
Presentation Time: 1:30 p.m. ET
Learn more about CRISPR2.0 and register to participate here: https://crispr-conference.com/
About Epicrispr Biotechnologies
Epicrispr Biotechnologies is a leading epigenetic editing company, leveraging the power of CRISPR without cutting DNA. The company’s proprietary Gene Expression Modulation System (GEMS) includes the smallest Cas protein known to work in human cells, enabling in vivo or ex vivo delivery via a single viral vector. Epicrispr’s lead program, EPI-321, is in IND-enabling studies for the treatment of facioscapulohumeral muscular dystrophy (FSHD); additional programs seek to address alpha-1 antitrypsin deficiency (A1AD), heterozygous familial hypercholesterolemia (HeFH), and other indications. Visit www.epicrispr.com for more information or follow us on Twitter and LinkedIn.
Investor Contact
Shawn M. Cox
Epicrispr Biotechnologies
Manager, Investor Relations, and Corporate Communications
shawn.cox@epic-bio.com
Media Contact
Lisa Raffensperger
Ten Bridge Communications
lisa@tenbridgecommunications.com
(617) 903-8783